icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
DKDhdATvxgt50fP6